- Mid-size global pharma company preparing for the launch of follow-on indications in rheumatology and dermatology
- We helped the company strengthen the evidence package and developed value material tailored to multiple stakeholders in EU
- We guided the affiliates in minimizing the pricing impact for the product across EMEA countries
- Small biotech company preparing for its first commercial launch in rheumatology
- We helped the company designing the market access & pricing organizational structure and governance bodies from global to affiliate level
- We set-up the price management processes, SOPs, and IT systems to manage launch price setting and management
- An interface was developed to connect the intelligence collected by field teams (through a mobile app) and the global governance process
- Small biotech company in late-stage development for an orphan drug in pulmonary fibrosis
- We defined the global market access and pricing strategy for the asset both as monotherapy and as add-onto SoC
- We worked with the clinical team and with KOLs to ensure a robust evidence package to fit the needs of payers and HTAs in key markets
- Large pharma company developing a new prevention approach for influenza. SoC for broad influenza prevention include well established, and low-priced, products.
- We defined the specific target patient population where the product will fill a high unmet need.
- We worked with the cross-functional team to shape the Clinical Development Plan to address the needs from various decision-makers and influencers
- We developed the access & evidence strategy to differentiate the compound and ensure successful market access & pricing in key markets
- Our client was evaluating the potential in-licensing of an asset for the treatment of Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI)
- We provided epidemiology, pricing & reimbursement input in the product’s valuation
- Given the wide range of incidence rates of hospitalized MRSA BSI, we led an epidemiology study using EHR data and triangulated with literature data to narrow down the estimated incidence of events in the USA
- The product valuation, including these estimates, was successfully presented to client’s senior leadership for decision-making in structuring the deal terms proposal